StockData

HUTCHMED (China) vs Legend Biotech

HCM and LEGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HCM and LEGN compare

Legend Biotech grew revenue faster over the last twelve months (59.5% versus −13.0% for HUTCHMED (China)).

HUTCHMED (China) scores higher on the StockData Score (5 against 3 for Legend Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHCMLEGN
Size and price
Share price$14.40$16.11
Change, 1 year−4.5%−46.8%
Change, 5 years−59.1%−70.2%
Beta (5Y)0.750.80
Employees1092,900
StockData Score
Total score5 (better)3
Valuation score00
Growth score02 (better)
Performance score3 (better)0
Health score2 (better)1
Dividend score00
Growth
Revenue growth (TTM)−13.0%59.5% (better)
Revenue growth, 5Y average19.2%68.8% (better)
Net income growth (TTM)1111%–
EPS growth (TTM)1200%–
Profitability
Gross margin38.7%57.2% (better)
Operating margin−7.1%−4.3% (better)
Net margin83.3%–
FCF margin−14.4%−9.6% (better)
Return on equity36.7%–
Financial health
Debt / equity0.09–
Interest coverage−13.7×−2.5× (better)
Current ratio5.64 (better)3.04
Piotroski F-score4–
Ownership
Held by institutions0.51%28.4%
Held by insiders0.44%0.50%
Insider net buying, 12 months–−$384K
Superinvestors holding–1

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.